Viatris Inc VTRS

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, Viatris supplies high-quality medicines to approximately 1 billion patients around the world each year. The Company has a global footprint, an extensive portfolio of medicines that is well-diversified across therapeutic areas, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges.

Viatris' executive management team is focused on ensuring that the Company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers and other key stakeholders. The Company operates in more than 165 countries and territories with more than 30,000 employees. The Company has 27 manufacturing, packaging, and distribution sites worldwide, more than 1,400 approved molecules, and what we believe is industry leading commercial, R&D, regulatory, manufacturing, legal and medical expertise. Viatris' portfolio consists of generics (including complex products), globally recognized iconic brands, and an expanding portfolio of innovative medicines. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.

Last close 18.00 2026-10-23
Market cap $20.67B 2026-06-30 share count
52-week range 9.92 - 18.75

Valuation FY2025 figures against the last close

P/S1.5x
P/E—
P/FCF10.7x
EV/EBITDA249.4x
Dividend yield—
Diluted EPS-3.00

Where the revenue comes from as reported in the latest 10-K

Revenue by segment

  • Developed Markets
  • Greater China
  • Emerging Markets
  • Janz
Revenue by segment, 4 categories over 3 years. The same figures are in the table below. FY2025 Developed Markets, FY2025: 8.5B (59.7%) 60% Developed Markets Greater China, FY2025: 2.3B (16.4%) 16% Greater China Emerging Markets, FY2025: 2.2B (15.5%) 16% Emerging Markets Janz, FY2025: 1.2B (8.4%) 8% Janz FY2024 Developed Markets, FY2024: 8.9B (60.8%) 61% Greater China, FY2024: 2.2B (14.7%) 15% Emerging Markets, FY2024: 2.3B (15.3%) 15% Janz, FY2024: 1.3B (9.2%) 9% FY2023 Developed Markets, FY2023: 9.3B (60.1%) 60% Greater China, FY2023: 2.2B (14.0%) 14% Emerging Markets, FY2023: 2.6B (16.6%) 17% Janz, FY2023: 1.4B (9.3%) 9%
Segment FY2025FY2024FY2023
Developed Markets $8.51B $8.93B $9.25B
Greater China $2.33B $2.17B $2.16B
Emerging Markets $2.21B $2.25B $2.55B
Janz $1.19B $1.35B $1.42B

As the company reported it, from the “Segment Information (Reconciliation of Segment Information to Total Consolidated Information) (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $14.25B$14.69B$15.39B$16.22B$17.81B$11.82B$11.37B$11.27B—
Cost of revenue $9.29B$9.12B$8.99B$9.77B$12.31B$8.15B$7.60B$7.43B—
Gross profit $5.01B$5.62B$6.44B$6.50B$5.58B$3.80B$3.90B$4.00B—
R&D ————$751.1M$555.1M$639.9M$704.5M—
SG&A $3.79B$4.10B$4.07B$4.18B$4.53B$3.34B$2.56B$2.44B—
Total operating expenses $7.68B$5.61B$5.67B$4.88B$5.61B$4.01B$3.18B$3.10B—
Operating income -$2.66B$10.1M$766.2M$1.61B-$34.0M-$210.8M$715.5M$905.6M—
Interest expense $471.3M$550.0M$573.1M$592.4M$636.2M$497.8M$517.3M$542.3M—
Pre-tax income -$3.67B-$623.2M$202.9M$2.81B-$664.4M-$721.2M$154.4M$298.4M—
Income tax $150.1M$11.0M$148.2M$734.6M$604.7M$51.3M$137.6M$54.1M—
Net income -$3.51B-$634.2M$54.7M$2.08B-$1.27B-$669.9M$16.8M$352.5M—
EPS, basic -3.00-0.530.051.71-1.05-1.110.030.69—
EPS, diluted -3.00-0.530.051.71-1.05-1.110.030.68—
Shares, diluted (wtd. avg.) ——1.21B1.22B1.21B601.2M516.5M516.5M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $1.32B$734.8M$991.9M$1.26B$706.2M$850.0M$491.1M$389.3M$369.9M
Short-term investments $40.7M$38.0M$37.0M$35.3M$38.2M$39.1M———
Receivables $3.03B$3.22B$3.70B$3.81B$4.27B$4.84B$3.06B——
Inventory $4.00B$3.85B$3.47B$3.52B$3.98B$5.47B$2.67B——
Total current assets $9.79B$9.52B$12.98B$10.64B$10.90B$12.87B$6.76B——
Property, plant and equipment $2.61B$2.67B$2.76B$3.02B$3.19B$3.46B$2.15B——
Goodwill $6.75B$9.13B$9.87B$10.43B$12.11B$12.35B$9.59B$9.75B—
Other intangibles $15.10B$17.07B$19.18B$22.61B$26.13B$29.68B$11.65B——
Total assets $37.19B$41.50B$47.69B$50.02B$54.84B$61.55B$31.26B——
Short-term debt $1.93B$8.3M$1.94B$1.26B$1.88B$2.31B$1.51B——
Total current liabilities $7.09B$5.78B$7.78B$6.75B$9.88B$10.56B$5.57B——
Long-term debt $12.48B$14.04B$16.19B$18.02B$19.72B$22.43B$11.21B——
Total liabilities $22.48B$22.87B$27.22B$28.95B$34.35B$38.60B$19.37B——
Retained earnings -$388.3M$3.42B$4.64B$5.18B$3.69B$5.36B$6.03B——
Total equity $14.71B$18.64B$20.47B$21.07B$20.49B$22.95B$11.88B$12.17B$13.31B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $2.32B$2.30B$2.90B$3.00B$3.02B$1.23B$1.80B$2.34B—
Depreciation and amortisation $2.80B$2.89B$2.74B$3.03B$4.51B$2.22B$2.02B$2.11B—
Stock-based compensation $177.7M$146.1M$180.7M$116.4M$111.2M$79.2M$56.8M-$3.3M—
Capital expenditure $378.8M$326.0M$377.0M$406.0M$457.2M$243.0M$213.2M$252.1M—
Investing cash flow -$427.7M$1.80B-$864.5M$1.47B-$117.8M-$301.1M-$525.4M-$1.21B—
Financing cash flow -$1.29B-$4.33B-$2.30B-$3.88B-$3.01B-$605.7M-$1.17B-$1.09B—
Buybacks $500.5M$250.0M$250.0M$0$0$0$0$432.0M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001792044-26-000013.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -10B 0 10B 20B Revenue, FY2018: 11.3B Gross profit, FY2018: 4B Net income, FY2018: 352.5M Revenue, FY2019: 11.4B Gross profit, FY2019: 3.9B Net income, FY2019: 16.8M Revenue, FY2020: 11.8B Gross profit, FY2020: 3.8B Net income, FY2020: -669.9M Revenue, FY2021: 17.8B Gross profit, FY2021: 5.6B Net income, FY2021: -1.3B Revenue, FY2022: 16.2B Gross profit, FY2022: 6.5B Net income, FY2022: 2.1B Revenue, FY2023: 15.4B Gross profit, FY2023: 6.4B Net income, FY2023: 54.7M Revenue, FY2024: 14.7B Gross profit, FY2024: 5.6B Net income, FY2024: -634.2M Revenue, FY2025: 14.3B Gross profit, FY2025: 5B Net income, FY2025: -3.5B FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $11.27B $11.37B $11.82B $17.81B $16.22B $15.39B $14.69B $14.25B
Gross profit — $4.00B $3.90B $3.80B $5.58B $6.50B $6.44B $5.62B $5.01B
Net income — $352.5M $16.8M -$669.9M -$1.27B $2.08B $54.7M -$634.2M -$3.51B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Material agreement signed Item 1.01
  • New debt or obligation Item 2.03
  • Other event Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Other event Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%